Wells Fargo analyst Michael Turrin maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overw

NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a b

JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight

Deutsche Bank AG purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) in the un

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Over

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a B

Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy

Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Ove

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares are up during Thursday's premarket session on th

Ultragenyx shares rise after FDA approval of Genglycos, with a $2.7 million wholesale cost and $362

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Ultragenyx Pharmaceutical NASDAQ: RARE said the U.S. Food and Drug Administration has approved GENGL

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Di

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a

Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q

The U.S. Food and Drug Administration approved ​Ultragenyx Pharmaceutical's gene therapy to ‌treat a

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the U.S. Food and Drug Administrat

GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approv

Ultragenyx Pharmaceutical is rated a soft Buy at $26.75, with a probability-weighted fair value of ~

Assenagon Asset Management S.A. lowered its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDA

he litigation, which was filed in the United States District Court for the District of New Jersey, r

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ultragenyx Pharmaceutical (NASDAQ:R

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE - Get Free Report)'s share price gapped up before the m

RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Ove

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical NASDAQ: RARE reported second-quarter 2026 revenue of $214 million, led by

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business perfor

Ultragenyx (RARE) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estima

Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(0.90) per share which beat th

Second quarter total revenue of $214 million,  Crysvita® revenue of $156 million and Dojolvi® revenu

Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a

NOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a b

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earn

Entropy Technologies LP grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) by 80.9%

RBC Capital analyst Luca Issi maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform

U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps lea

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and

Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Ove

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and

Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight

Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Over